⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Figure 1 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka Elizabeth A. Daugherity Amanda L. McCormick Trevor S. Anderson Savanna L. Smith Caryn Lawrence Duke Appiah Devin B. Lowe

View at Publisher

Ask AI

Bookmark

Share

Key Points

Core finding indicates the bispecific antibody enhances the antitumor effects of regorafenib in colon cancer.
ICD induction in CT26 cells was observed following exposure to regorafenib, supporting increased efficacy.
The experimental approach utilized supplementary figure data to analyze the induction of ICD after treatment.
These findings could suggest new therapeutic strategies for improving colon cancer treatment outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Supplementary figure highlights ICD induction in CT26 after regorafenib exposure, suggesting enhanced antitumor activity.

Abstract

Supplementary Figure 1 shows ICD induction in CT26 following REG exposure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0209 https://doi.org/10.1158/1535-7163.29760656

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
2Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
3Supplementary Figure 3 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
4Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
5Supplementary Figure 9 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025

Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025
Supplementary Figure 7 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer2025